MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX)

About MLTX

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and p…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

130

Website

www.moonlaketx.com

Fundamentals

1-day range

$16.3$16.67

Market cap

$1.33B

P/E (trailing)

—

P/E (forward)

-4.93

EPS (trailing)

$-3.84

Dividend yield

—

Beta

1.07

Avg. volume

1.21M

Forecasts

13 analyst ratings

MoonLake Immunotherapeutics Class A Ordinary Shares Competitors

Chosen by industry and closest market cap.

• MLTX

  MoonLake Immunotherapeutics Class A Ordinary Shares

  $14.99

  ▼ 3.48%
  Market cap $1.33BP/E —
  $5.95$62.75
• SDGR

  Schrodinger Inc. Common Stock

  $19.7

  ▼ 3.48%
  Market cap $1.33BP/E —
  $10.95$23.02
• LBRX

  LB Pharmaceuticals Inc Common Stock

  $47.8

  ▼ 0.20%
  Market cap $1.38BP/E —
  $13.36$50.16
• ETON

  Eton Pharmaceuticals Inc. Common Stock

  $59.79

  ▼ 4.60%
  Market cap $1.26BP/E 150.92
  $14.27$66.37
• MNKD

  MannKind Corporation Common Stock

  $3.96

  ▼ 2.59%
  Market cap $1.24BP/E —
  $2.23$6.51
• SPTX

  Seaport Therapeutics Inc. Common Stock

  $24.04

  ▼ 8.42%
  Market cap $1.24BP/E —
• PAHC

  Phibro Animal Health Corporation Class A Common Stock

  $37.64

  ▲ 3.55%
  Market cap $1.44BP/E 14.51
  $28.25$60.08

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

63.67M

Total value held

$1.15B

Institutional holders

143